Last reviewed · How we verify

NCT03172403: MYOCAC

Skeletal Muscle Expression of Myostatin and Cancer of Digestive System Associated Cachexia

Terminated NA Last updated 25 August 2022
What this trial tests

NA trial testing Height and weight in Cancer of Digestive System in 3 participants. Terminated before completion.

Timeline
2 August 2018
Primary endpoint
3 January 2019
1 August 2019

Quick facts

Lead sponsorCentre Hospitalier Universitaire de Saint Etienne
PhaseNA
StatusTerminated
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposebasic science
Enrollment3
Start date2 August 2018
Primary completion3 January 2019
Estimated completion1 August 2019
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

Centre Hospitalier Universitaire de Saint Etienne

Who can join

Adults 40 to 80, any sex, with Cancer of Digestive System. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Cancer cachexia is responsible for the death of approximately 20% of patients. Myostatin is a master negative regulator of skeletal muscle mass. If the role of myostatin in cancer cachexia is now well established in murine models, no study has focused on muscle expression of Myostatin in relation to the degree of cachexia. the hypothesize is that muscle Myostatin a biological marker of cachexia in patients with cancer of digestive system. The main objective is to compare skeletal muscle Myostatin messenger RiboNucleic Acid (mRNA) level as a function of cachexia in cancer of digestive system patients. Myostatin messenger RiboNucleic Acid (mRNA) level will be determined in a muscle sample taken during the resection under general anaesthesia. Skeletal muscle index will be determined before surgery, 3 and 6 months after surgery. Muscle strength of the lower and upper limbs will be determined before resection, at 1 month, 3 months and 6 months postoperatively. Blood sampling will also be performed on these 4 occasions.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Centre Hospitalier Universitaire de Saint Etienne trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03172403.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing